Research programme: peptide therapeutics - SymThera
Latest Information Update: 02 Nov 2016
At a glance
- Originator SymThera
- Class Peptides
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Duchenne muscular dystrophy
Most Recent Events
- 02 Nov 2016 Early research in Duchenne muscular dystrophy in USA (Parenteral) before November 2016 (SymThera website, November 2016)